30 Oct H. Stewart Parker Joins Impel’s Board of Directors
SEATTLE, Wash., October 30, 2014 – Impel NeuroPharma is pleased toannounce that H. Stewart Parker, a prominent leader in Seattle’s Biotechnology community, has joined Impel’s Board of Directors.
Most recently, Parker was the CEO of the Seattle-based Infectious Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines, and treatments for neglected diseases. Parker started her career in biotech as the first employee of Immunex, growing with the company to become Vice President of Corporate Development. In 1992, Parker founded the Immunex offshoot Targeted Genetics, a Seattle biotech company focused on developing gene-based treatments for acquired and inherited disease. Parker served as President and CEO of Targeted Genetics for seventeen years until her retirement in 2008.
Parker has since been active on a number of boards, including the University of Washington’s College of Arts & Science, C3 Jian, OncoGenex Pharmaceuticals, and Sangamo BioSciences. Parker is a graduate of the MBA program at the University of Washington’s Foster School of Business with an undergraduate degree in Slavic languages and literature.
“Stewart is an acknowledged leader in the biotechnology community, building multiple organizations and working with teams to scale their operations,” notes Mike Hite, Impel’s CEO; “For us, Stewart is bringing an exceptional amount of experience and strategic perspective that will be beneficial as Impel establishes its future course and the next stage of growth.”
About Impel NeuroPharma:
Impel NeuroPharma, Inc., is developing a novel intranasal device to enable drugs to bypass the blood-brain barrier using direct nose-to-brain delivery. Impel’s technology can dramatically improve the delivery of drugs, including biologics, into the brain and central nervous system. Nose to brain delivery may enable molecules previously unable to cross the blood-brain barrier to become therapeutics, potentially aiding treatment to some of the most common and devastating neurological conditions such as Alzheimer’s and Parkinson’s.
About the Precision Olfactory Delivery Technology:
Impel NeuroPharma’s Precision Olfactory Delivery (POD) device platform delivers aerosolized drugs to the upper nasal cavity where they are directly transported into the brain, effectively bypassing the blood-brain barrier. Drug molecules can reach the brain faster, in greater amounts, and with improved patient experience than with alternate delivery methods such as intravenous or intrathecal dosing.